Document is current

Article History

Received: 22 September 2025

Accepted: 26 November 2025

First Online: 12 January 2026

Declarations

:

: Motaz Ashkar, MBBS, MS: Advisory and consulting for Amgen. Jodie A. Barkin, MD: Scientific advisor for AbbVie, Aimmune therapeutics, Corevitas, Organon, Amgen. Jennifer Geremia MSPAS, PA-C: Advisory board member, speaker and consultant for Madrigal; Advisory board member and speaker for Ipsen and Pfizer; Speaker and consultant for AbbVie; Speaker for Nestle, Lilly and Phathom; Advisory board member for Takeda. Min Yang, MD, Viviana Garcia-Horton, PhD, Marie Louise Edwards, MS,: Employees of Analysis Group, Inc., which has received consulting fees from AbbVie for the conduct of this research. Yuehan Zhang, PhD: Was an employee of Analysis Group, Inc., at the time of the research, which has received consulting fees from AbbVie for the conduct of this research. Dr. Zhang is currently an employee of Johnson and Johnson Innovative Medicine and may own stock. Zach Baldwin, PharmD, Eric Shen, PharmD, Douglas E. Dylla, PhD, Yuri Sanchez Gonzalez, PhD: Employees of AbbVie and may own stock.

: All HCPs who confirmed their eligibility to participate consented before proceeding with survey completion. To mitigate against potential bias in the study, HCP respondents remained unaware of the study sponsor, and the sponsors were blinded to the HCPs’ identities. The study was determined to be exempt from institutional review board (IRB) review according to 45 CFR 46.104(d)(2) by Pearl IRB as it involved only the secondary use of data that were de-identified.